News and Announcements
Actinogen Medical Present Xanamem Research at CTAD
- Published December 06, 2016 3:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th December 2016, ASX Announcement
Actinogen Medical Limited (ASX:ACW) is pleased to announce the presentation of the latest Xanamem™ research data at CTAD (Clinical Trials in Alzheimer’s Disease) in San Diego. The paper: Xanamem™: an 11ß-HSD1 Inhibitor in current development for the management of Alzheimer’s disease (AD), will be presented by Prof Craig Ritchie on Friday the 9th December.
CTAD is one of the most prestigious international Alzheimer’s congresses, where the latest ground-breaking research into Alzheimer’s disease is showcased. CTAD focuses on promising new Alzheimer’s drugs under development. This presentation follows on from the very successful presentations of Xanamem™ at AAIC (Alzheimer’s Association International Congress) in Toronto, ICE (the International Congress of Endocrinology) in Beijing and Mastering Medicinal Chemistry in Lisbon, over the past few months.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
